Editorial Standards

Editorial Independence

Retatrutide Knowledge Base is editorially independent. We do not accept funding, advertising, sponsorship, or content placement from Eli Lilly, any other pharmaceutical manufacturer, compounding pharmacy, telehealth provider, or peptide supplier. We do not sell retatrutide or any other product. We have no commercial relationship with the entities we cover.

We may receive newsletter signups and reader feedback through this site. We do not sell, rent, or share reader data with third parties.

Source Quality Hierarchy

We work backwards from the strongest available evidence to the weakest, and we cite sources by name and link directly when possible.

1. Tier 1 — Peer-reviewed publication. NEJM, Lancet, Diabetes, Diabetes Care, JAMA, Nature Medicine, and similar journals. Preferred for all efficacy and safety claims when available.
2. Tier 2 — Conference abstracts and presentations. ADA, EASD, ObesityWeek, ENDO Scientific Sessions. Used when peer-reviewed paper is not yet published, with the publication-pending status explicitly noted.
3. Tier 3 — Manufacturer press release and SEC filings. Eli Lilly investor relations announcements, 8-K filings, earnings transcripts. Used for topline results before peer-reviewed publication; clearly labeled as "press release" with the date.
4. Tier 4 — Regulatory and trial registry data. FDA, EMA, ClinicalTrials.gov, trial protocol publications. Authoritative for design, status, enrollment, and regulatory milestones.
5. Tier 5 — Independent medical journalism. Reuters, Bloomberg, STAT, Endpoints, BioSpace. Used as secondary context and cross-reference, never as the sole basis for a clinical or numerical claim.

We do not cite forums, anecdotal social media reports, compounding pharmacy marketing material, or AI-generated summaries as primary sources.

Evidence Levels on Articles

Knowledge base articles carry an explicit evidence level so readers can calibrate how much weight to put on the claim:

• High — supported by Phase 3 randomized controlled trial data, FDA review documents, or multiple independent Phase 2 trials with consistent results.
• Moderate — supported by a single Phase 2 trial, mechanistic data with clinical signal, or strong cross-trial inference.
• Low — supported by Phase 1 data, animal models, expert commentary, or extrapolation from class-effect of related drugs.
• Emerging — early signals, preprints, or pending readouts that may change materially as more data become available.

What We Write About — and What We Don't

We write about: mechanism of action, clinical trial design and results, safety and tolerability data, regulatory status, comparisons against approved and investigational drugs, and the development pipeline.

We do not write: dosing recommendations for individual patients, sourcing or purchasing guidance, prescription writing advice, instructions for self-administration, or anything that could be reasonably read as encouragement to obtain retatrutide outside of authorized clinical trials. Where reader interest in those topics is high (cost, availability, "how to get"), we cover the regulatory and access landscape only — never specific vendors or product instructions.

Update Cadence

• Trial pages are updated within 48 hours of a public readout (press release, conference presentation, or peer-reviewed publication).
• Knowledge base articles are reviewed at least quarterly and whenever significant new data are published, then re-dated.
• Comparisons and competitor data are updated when the competitor releases new data or changes regulatory status.
• Every page displays both a "Published" and a "Last Updated" date.

Review Process Per Article

1. Source identification. Editorial team identifies primary sources from PubMed, ClinicalTrials.gov, FDA databases, conference proceedings, and manufacturer disclosures.
2. Drafting. Article is drafted with inline citations to specific sources. Each numerical claim is traceable to a named source.
3. Medical review. Dr. Valentina Dzartovska, MD reviews for clinical accuracy, appropriate interpretation, and evidence-based framing. Subspecialty review from endocrinology and obesity medicine is added when material warrants it.
4. Revision and publication. Feedback is incorporated and the article is published with explicit dates and source links.
5. Ongoing audit. Articles are re-reviewed at least quarterly. When data change, articles are updated and the change is reflected in the "Last Updated" date. Material corrections are noted in a correction notice (see below).

Corrections Policy

We correct factual errors promptly and openly. To report a possible error:

• Email info@retatrutide.med with the URL, the specific claim in question, and the source you believe contradicts it.
• We acknowledge corrections within 5 business days and aim to publish or reject the correction within 14 days, depending on the complexity of the verification.
• When a material correction is made, we note the correction at the bottom of the affected article, including the date and a summary of what changed.
• We do not silently edit articles to remove embarrassing claims; substantive changes are documented.

AI Assistance Disclosure

We use AI tools to assist with research synthesis, draft generation, and copy editing. Every published article is read, verified against cited sources, and edited by the human editorial team before publication. Medical claims are cross-checked against primary sources by Dr. Dzartovska. AI is not used to generate clinical numerical claims that are not traceable to a cited source.

The retatrutide.med chat assistant is powered by an OpenAI language model, with its knowledge base scoped to content published on this site. It is rate-limited and clearly labeled as an AI assistant providing educational information only.

Conflict of Interest Disclosure

The editorial team and reviewer hold no financial interest in Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Amgen, Altimmune, Zealand Pharma, or any company developing or marketing GLP-1, GIP, glucagon, or amylin receptor therapeutics, beyond ordinary public stock ownership that may be present in diversified retirement accounts.

We will publicly disclose any material change in this status before the affected content is published.

Limitations We Acknowledge

• We are a relatively new, niche, single-topic publisher. We do not have the scale of Mayo Clinic, NIH, or NEJM, nor the primary-research access of Eli Lilly.
• Some content predates a Phase 3 readout that has since been published. We work to keep these articles current but readers should always check the "Last Updated" date.
• Retatrutide is investigational. Many of the most important questions — durability of effect after discontinuation, cardiovascular outcomes, long-term safety, real-world effectiveness — are not yet answerable from published evidence.

Contact

For corrections, source suggestions, or editorial feedback: info@retatrutide.med.

Related: Medical Reviewer · Sources & Methodology · About